This Week in Cardiology cover image

Mar 3 2023 This Week in Cardiology

This Week in Cardiology

00:00

Cantivv Macarbal First Selective Cardiac Myosin Inhibitor

FDA declined to approve cantivv macarbal first selective cardiac myosin activator. FDA cited a lack of evidence for efficacy but galactic HF trial was technically positive with omocantiv macarbal reducing the primary endpoint of first heart failure visit or CV death. ACC preview starts tomorrow in New Orleans and I'm taping this at like 3.30 a.m. because I have an early flight to New Orleans so if you're in New Orleans please say hello.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app